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Aims Incomplete endothelialization has been found to be associated with late stent thrombosis, a rare but devastating
phenomenon, more frequent after drug-eluting stent implantation. Optical coherence tomography (OCT) has 10
times greater resolution than intravascular ultrasound and thus appears to be a valuable modality for the assessment
of stent strut coverage. The LEADERS trial was a multi-centre, randomized comparison of a biolimus-eluting stent
(BES) with biodegradable polymer with a sirolimus-eluting stent (SES) using a durable polymer. This study sought
to evaluate tissue coverage and apposition of stents using OCT in a group of patients from the randomized
LEADERS trial.
Methods
and results
Fifty-six consecutive patients underwent OCT during angiographic follow-up at 9 months. OCT images were
acquired using a non-occlusive technique at a pullback speed of 3 mm/s. Data were analysed using a Bayesian hier-
archical random-effects model, which accounted for the correlation of lesion characteristics within patients and
implicitly assigned analytical weights to each lesion depending on the number of struts observed per lesion.
Primary outcome was the difference in percentage of uncovered struts between BESs and SESs. Twenty patients
were included in the analysis in the BES group (29 lesions with 4592 struts) and 26 patients in the SES group (35
lesions with 6476 struts). A total of 83 struts were uncovered in the BES group and 407 out of 6476 struts were
uncovered in the SES group [weighted difference 21.4%, 95% confidence interval (CI) 23.7 to 0.0, P ¼ 0.04].
Results were similar after adjustment for pre-procedure lesion length, reference vessel diameter, number of
implanted study stents, and presence of stent overlap. There were three lesions in the BES group and 15 lesions
in the SES group that had 5% of all struts uncovered (difference 233.1%, 95% CI 261.7 to 210.3, P, 0.01).
Conclusion Strut coverage at an average follow-up of 9 months appears to be more complete in patients allocated to BESs when
compared with SESs. The impact of this difference on clinical outcome and, in particular, on the risk of late stent
thrombosis is yet to be determined.
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Introduction
Until recently, trials comparing drug-eluting stents (DESs) and bare
metal stents (BMSs) used intravascular ultrasound (IVUS) to
confirm that DESs reduce restenosis and intimal proliferation.1–5
However, the thin layer of neointima observed after implantation
of DESs is often below the 100 mm axial resolution of IVUS.
Incomplete stent strut endothelialization has recently received
attention with studies suggesting an association with the long-term
risk of stent thrombosis,6 but it cannot be detected by IVUS.
Optical coherence tomography (OCT) has 10 times greater resol-
ution than IVUS and thus appears to be an improved imaging
modality for the assessment of tissue coverage of DESs. Observa-
tional data using OCT in first-generation sirolimus-eluting stents
suggest that stent struts may still remain uncovered 2 years after
implantation.7 Evidence of a small but clear increase of late stent
thrombosis has led to the increase in the duration of dual anti-
platelet therapy beyond the customary 3–6-month period of the
initial DES trials,8,9 with 1 year now recommended by the AHA/
ACC/SCAI guidelines,10 mainly based on theoretical reasoning,
without robust studies supporting this recommendation.
The LEADERS (Limus Eluted from A Durable vs. ERodable Stent
coating) study was a multi-centre, randomized non-inferiority trial
comparing a biolimus-eluting stent (BES) using a biodegradable
polymer with a widely used sirolimus-eluting stent (SES) with a
durable polymer. At 9 months, BESs were non-inferior to SESs
for the primary composite endpoint of cardiac death, myocardial
infarction (MI), or clinically indicated target vessel revascularization
(TVR).11 Frequency of cardiac death, MI, and clinically indicated
TVR were similar for both stent types (composite endpoint of
9.1% for BESs, 9.9% for SESs, P ¼ 0.59). In the angiographic sub-
study, BESs were non-inferior to SESs in in-stent percentage diam-
eter stenosis at 9-month follow-up with an in-stent restenosis rate
of 5.5 vs. 8.7% (P ¼ 0.20), respectively.11
Durable polymer surface coatings may be one of the causes for
incomplete endothelialization of first-generation DESs. The BES
uses biodegradable polylactic acid, which is co-released with bioli-
mus during 6–9 months and degrades into carbon dioxide and
water. Since the stainless steel surface of the BES used in the
LEADERS trial is free of additional primer permanent polymer
coating (e.g. parylene that is present in the currently available Bio-
matrix stent; Biosensors, Singapore), only the metal stent back-
bone remains in situ once the polymer has degraded. A second
feature distinguishing BESs and SESs is that the coating is only
abluminal, possibly favouring endothelialization of the stent. In a
sub-study of the LEADERS trial, we therefore set out to
compare tissue coverage and apposition between BESs and SESs
using OCT. The primary endpoint was the difference in percentage
of uncovered struts between BESs and SESs.
Methods
The design of the LEADERS study has been published elsewhere.11 The
study applied an ‘all-comers’ approach including patients aged 18 years or
morewith chronic stable coronary artery disease or acute coronary syn-
dromes, including non-ST-elevation and ST-elevation MI. There was no
limit for the number of treated lesions, vessels, or lesion length, and no
patients were excluded on the basis of co-morbid disorders or age, apart
from the following pre-specified criteria: known allergy to acetylsalicylic
acid, clopidogrel, heparin, stainless steel, sirolimus, biolimus, or contrast
material; planned surgery within 6 months of percutaneous coronary
intervention (PCI) unless the dual anti-platelet therapy could be main-
tained throughout the peri-surgical period; pregnancy; participation in
another trial before reaching the primary endpoint; and inability to
provide informed consent. All patientswere discharged on acetylsalicylic
acid of at least 75 mg daily indefinitely and clopidogrel 75 mg daily for at
least 12months. The study compliedwith theDeclaration ofHelsinki and
was approved by all institutional ethics committees. The trial is registered
with ClinicalTrials.gov, number NCT00389220. All patients provided
written informed consent for participation in this trial.
Randomization was done centrally after diagnostic coronary angio-
graphy and before PCI by use of a telephone allocation service.
Patients were randomly allocated on a one-to-one basis to treatment
with BESs (BioMatrix Flex, Biosensors, Inc., Newport Beach, CA, USA)
or SESs (Cypher SELECT, Cordis, Miami Lakes, FL, USA), and to active
angiographic follow-up at 9 months or clinical follow-up only on a 1:3
basis using a factorial design. The OCT sub-study was performed at
two of the 10 LEADERS sites (Royal Brompton Hospital, London,
UK, n ¼ 12, and Thoraxcenter, Erasmus Medical Center, Rotterdam,
the Netherlands, n ¼ 34). Randomized patients were eligible if
they underwent follow-up angiography. Exclusion criteria specific to
follow-up with OCT imaging were renal impairment (serum creatinine
200 mmol/L) and left ventricular ejection fraction ,30%. The OCT
sub-study was approved by the trial steering committee and local
institutional review boards.
Optical coherence tomography
For the purpose of this study, OCT was performed at follow-up only
using the M3 system (LightLab Imaging, Westford, MS, USA) at 20
frames per second allowing retrieval of the imaging core at 3 mm/s
for 30 s (90 mm) with a non-occlusive imaging technique,12 following
administration of intravenous heparin and intracoronary nitrates. A
standard guide wire was advanced distally in the target vessel. A
single lumen (e.g. Transit, Cordis, Johnson & Johnson, Miami, FL,
USA or ProGreat, Terumo Co., Tokyo, Japan) or a double lumen cath-
eter (0.02300 TwinPass, Vascular Solutions, Inc., Minneapolis, MN, USA)
was then advanced distal to the previously stented region. Following
withdrawal of the guide wire, the optical ImageWire (LightLab
Imaging, Westford, MS, USA) was passed through the catheter and
OCT imaging commenced at a pullback of 3.0 mm/s, during flush of
2–4 mL/s of iso-osmolar contrast (Iodixanol 320, VisipaqueTM, GE
Health Care, Cork, Ireland) through the guiding catheter to replace
blood flow and permit visualization of the stented segment and
intima–lumen interface. Scanning was prematurely terminated if
there was any haemodynamic instability, arrhythmia, or patient intoler-
ance. If the stented segment was too long to be safely imaged in a
single pullback, image acquisition was stopped and re-commenced
from the same position during a second contrast injection. Anatomic
landmarks such as side branches, calcifications, or stent overlap seg-
ments were used for longitudinal view orientation.
Offline OCT data analysis was undertaken by an independent core
laboratory (Cardialysis BV, Rotterdam, the Netherlands) blinded to
stent-type allocation and clinical and procedural characteristics of
the patients. Analysis of contiguous cross-sections at 1 mm longitudinal
intervals within the stented segment was performed using proprietary
software (LightLab Imaging, Westford, MA, USA). Intra- and inter-
observer reliability were evaluated in previous studies and found to
be .0.95,13–15 as could be expected in view of the clear visualization
of intimal tissue and struts allowed by OCT. Recently, Barlis et al.16
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demonstrated a low intra- and inter-observer variability when asses-
sing OCT strut tissue coverage at follow-up (reproducibility coefficient
of 26.7 and 24.1 mm and intraclass correlation coefficient of 99.4 and
99.6%, respectively).
Metallic stent struts typically appear as bright, signal-intense struc-
tures with dorsal shadowing. The number of stent struts was deter-
mined in each cross-section. Stent coverage was classified as not
visible/incomplete when there were points of the stent struts with
no visible tissue coverage or as complete when tissue was seen over-
lying the strut. Thickness (mm) of the tissue coverage on the luminal
side of each strut was measured at the middle of the long axis of
the strut. A linear measurement line was drawn from the endoluminal
leading edge perpendicular to the long axis of the strut towards the
luminal leading edge of the strut. Struts were classified as apposed
(when the strut was in contact with the vessel wall) or malapposed
if protruding into the lumen at a distance greater than the strut thick-
ness (154 mm for the SES and 112 mm for the BES).
For malapposed struts, the presence of tissue was qualitatively
assessed also on the abluminal surface to confirm circumferential
coverage.
Sample size calculation and statistical
analysis
The OCT sub-study was a superiority study. To estimate differences
between BESs and SESs, we used a Bayesian hierarchical random-effects
model based on Markov chain Monte Carlo simulation methods with
vague priors.17 The model included random-effects at the level of
lesions and patients, fully accounting for the correlation of lesion charac-
teristics within patients and their variation between patients and
implicitly assigning analytical weights to each lesion depending on the
number of struts observed per lesion. The pre-specified primary end-
point of the sub-study was the difference in percentage of uncovered
struts between BESs and SESs. Assuming average numbers of 1.5
lesions per patients, 160 struts per lesion, and a design factor of 1.5
(defined as the standard error derived from the Bayesian hierarchical
random-effects model assuming clustering of lesions within patients
divided by the crude standard error derived from conventional analysis
assuming independency of lesions), we estimated that the inclusion of 22
patients per group would yield greater than 90% power to detect a
difference in uncovered struts of 4% between BESs and SESs at a two-
sided type I error of 0.05. Secondary endpoints were the differences
in percentage of malapposed struts and in percentage of malapposed
and uncovered struts. After logarithmic transformation of the data, we
also estimated the difference between groups in neointimal thickness.
Then, we determined differences in the percentage of lesions with any
struts with unfavourable outcome, with at least 5%, and with at least
10% of struts with unfavourable outcome, with unfavourable outcomes
defined in accordance with definitions used for primary and secondary
endpoints. In view of the baseline imbalance in the proportion of
lesions located in small vessels, we performed a post hoc sensitivity analy-
sis of the primary endpoint restricted to small vessels only.
Differences between groups were estimated from the median of the
posterior distribution of the 50 001–100 000 iterations, with the initial
50 000 iterations discarded as ‘burn-in’.We derived the 95% confidence
interval (95% CI) from the 2.5th and 97.5th percentiles of the posterior
Figure 1 Trial profile. }Two patients allocated to sirolimus-eluting stents and clinical follow-up only (two lesions) had a clinically indicated
angiography and underwent optical coherence tomography; *One patient allocated to biolimus-eluting stents (two lesions) had one lesion
excluded from the analysis for technical reasons; †Two patients allocated to sirolimus-eluting stents (four lesions) had one lesion excluded
each from the analysis for technical reasons.
LEADERS trial OCT sub-study 167
distribution, also calculating two-sided P-values from the posterior distri-
bution. 95% CI and P-values from posterior distributions can be inter-
preted similarly to the conventional 95% CI and P-values. Sensitivity
analyses were adjusted for pre-procedure lesion length, reference
vessel diameter, number of implanted study stents, and presence of
stent overlap. Finally, we restricted the analysis of the primary endpoint
to patients with analysable OCT data who had been randomly allocated
to angiographic follow-up. Baseline characteristics of lesions, procedural
results, and angiographic follow-up data were analysed as previously
described,8 using mixed maximum-likelihood logistic and linear
regression models that allowed for correlation of more than one
lesion within patients. Statistical analyses were performed using
WinBUGS version 1.4.3 (Imperial College and MRC, UK) and Stata,
version 10.0 (StataCorp, College Station, TX, USA).
Results
Figure 1 shows the profile of the OCT sub-study. Twenty-eight
patients allocated to BESs and 32 patients allocated to SESs
Figure 2 Examples of optical coherence tomography findings. (A) This 73-year-old male received a biolimus-eluting stent 9 months prior to
the right coronary artery. The stent is seen covered by a thin, uniform layer of tissue overlying all stent struts that are well apposed to the vessel
wall. (B) Offline optical coherence tomography analysis. A total of 14 stent struts are visible in this cross-section with the observer having
measured the thickness of tissue overlying each of the struts, expressed in the coloured panel (top left) in mm. The mean neointimal thickness
in this frame was 0.27 mm (270 mm). (C) Sirolimus-eluting stent struts are observed circumferentially. Struts between 7 and 11 o’clock are
apposed but uncovered by tissue. Struts from 1 to 5 o’clock are observed covered with a very thin layer of tissue (mean thickness
0.03 mm or 30 mm). The stent was implanted in a patient who received two sirolimus-eluting stents to the mid-left anterior descending
artery 9 months prior following a presentation with a non-ST-elevation myocardial infarction. He was asymptomatic at 9-month follow-up.
(D) Nine-month follow-up of a biolimus-eluting stent implanted in the left anterior descending artery across the diagonal bifurcation. A solitary
strut is observed (arrow) malapposed at the level of the carina. The strut was seen covered by a thick, uniform and homogenous tissue. (E) This
optical coherence tomography pullback frame from a 78-year-old male with prior stenting to the left anterior descending artery/diagonal bifur-
cation with a sirolimus-eluting stent. Struts are observed (1–3 o’clock) to be malapposed to the vessel wall with a heterogeneous tissue with
different signal attenuations that may represent thrombotic material. The patient was asymptomatic at 9-month follow-up and on dual anti-
platelet therapy. (F ) Left main coronary artery optical coherence tomography. This patient had a proximal left anterior descending stent
implanted 9 months prior. We extended the pullback beyond the stent into the left main coronary artery which demonstrates a well-
demarcated, non-flow limiting, low-attenuation plaque (12 o’clock) consistent with calcium. Our sub-study exclusively used a non-occlusive
technique for optical coherence tomography imaging that requires pullback of the image wire during simultaneous flush of contrast via the
guiding catheter. This is a significant advance over the traditional method of optical coherence tomography imaging in which a proximally posi-
tioned balloon is inflated during image acquisition. Hence, ostial and proximal segments of coronary arteries were all able to be imaged, thereby
supporting the ‘all-comer’ design of the LEADERS trial without any optical coherence tomography anatomical exclusions.
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were eligible for the sub-study, and 26 and 30 patients, respect-
ively, underwent OCT, all undertaken using the non-occlusive
technique. Figure 2 presents some examples of the spectrum of
OCT findings observed. Six patients in the BES and four patients
in the SES group were excluded from the analysis because of
low quality of OCT images. Twenty patients were included in
the analysis in the BES group (29 lesions with 4592 struts) and
26 patients in the SES group (35 lesions with 6476 struts).
Baseline clinical and angiographic characteristics of the 46 patients
are presented in Tables 1 and 2. Characteristics were similar in both
groups, except for differences in the percentage of patients with
small-vessel disease and in reference vessel andminimal lumen diam-
eter at lesion level. In addition, more patients had a history of
hypercholesterolemia in the SES group, even though overall choles-
terol levels were comparable between groups (4.31 mmol/L in the
BES vs. 4.17 mmol/L in the SES group, difference 20.13, 95% CI
20.90 to 0.63, P ¼ 0.73). The left anterior descending (LAD)
artery and the right coronary artery (RCA)were themost frequently
imaged vessels (Table 2). Procedural results were similar between
groups, with a trend towards smaller minimal lumen diameters
in-stent in patients allocated to SESs (Table 3). Control angiography
was performed at a median of 9.1 months (interquartile range 9.0–
9.3 months). Table 4 presents results of angiographic follow-up,
which were similar between groups and compatible with results of
the main trial.8
Optical coherence tomography analysis
Figure 3 shows a graphical representation of stent strut coverage in
lesions. Table 5 (top) presents results of the principal analysis of
the primary endpoint. A total of 83 out of 4592 struts in 29
lesions were uncovered in the BES group (weighted estimate
0.6%, 95% CI 0.2–1.6) and 407 out of 6476 struts in 35 lesions
were uncovered in the SES group (2.1%, 95% CI 0.9–4.4), with a
weighted difference between groups of 21.4% (95% CI 23.7 to
0.0, P ¼ 0.04). Results were similar after adjustment for pre-
procedure lesion length, reference vessel diameter, number of
implanted study stents, and presence of stent overlap (difference
22.0%, 95% CI 25.7 to 20.1, Table 6). None of the 41 struts
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Table 1 Baseline characteristics of patients
Biolimus-eluting stent (n5 20) Sirolimus-eluting stent (n 5 26) P-value
Age (years) 64.9 (10.2) 63.0 (11.4) 0.56
Males 14 (70.0%) 18 (69.2%) 0.61
Diabetes mellitus 4 (20.0%) 5 (19.2%) 1.00
Diabetes requiring insulin 2 (10.0%) 1 (3.9%) 0.40
Hypertension 10 (50.0%) 17 (65.4%) 0.37
Hypercholesterolaemia 9 (45.0%) 20 (76.9%) 0.04
Current smoker 5 (25.0%) 10 (38.5%) 0.37
Family history of CAD 11 (55.0%) 17 (65.4%) 0.55
History of MI 5 (25.0%) 9 (34.6%) 0.54
History of PCI 3 (15.0%) 6 (32.1%) 0.71
With drug-eluting stents 2 (10.0%) 1 (3.9%) 0.57
Previous CABG 1 (5.0%) 4 (15.4%) 0.37
Stable angina pectoris 12 (60.0%) 16 (61.5%) 1.00
Acute coronary syndrome 8 (40.0%) 10 (38.5%) 0.48
Unstable angina 1 (5.0%) 4 (15.4%)
Non-ST-elevation MI 2 (10.0%) 2 (7.7%)
ST-elevation MI 5 (25.0%) 4 (15.4%)
Multi-vessel disease 5 (25.0%) 3 (11.5%) 0.27
Small-vessel disease (RVD,2.75 mm) 8 (40.0%) 21 (80.8%) ,0.01
Study lesions per patient 0.89
One 12 (60.0%) 17 (65.4%)
Two 7 (35.0%) 7 (26.9%)
Three 0 (0.0%) 2 (7.7%)
Four or more 1 (5.0%) 0 (0.0%)
De novo lesions only 18 (90.0%) 25 (96.2%) 0.57
Long lesions (.20 mm) 7 (35.0%) 13 (50.0%) 0.38
Number of lesions per patient 1.5 (0.8) 1.4 (0.6) 0.71
Off-label use 14 (70.0%) 23 (88.5%) 0.15
Data are mean (SD) or number (%). P-values are from t-test for continuous and from Fisher’s test for categorical data. CAD, coronary artery disease; PCI, percutaneous coronary
intervention; CABG, coronary artery bypass grafting; MI, myocardial infarction; RVD, reference vessel diameter.
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located in areas with stent overlap were uncovered in the BES
group and six out of 235 struts in the SES group. Twelve lesions
in the BES group (41.4%) and 25 lesions in the SES group
(71.4%) were located in small vessels, with 24 out of 2207 struts
uncovered in BESs (weighted estimate 0.5%, 95% CI 0.1–2.0)
and 343 out of 4402 struts in SESs (weighted estimate 2.4%,
95% CI 0.9–5.4). When restricting the analysis to these lesions,
we found differences somewhat more pronounced (weighted
difference 21.8%, 95% CI 24.9 to 0.1, P ¼ 0.064). There were
two and eight lesions with 10% uncovered struts in the BES
and SES groups, respectively (difference 210.2%, 95% CI 230.9
to 1.3, P ¼ 0.08), 3 and 15 lesions with 5% uncovered struts
(difference 233.1%, 95% CI 261.7 to 210.3, P, 0.01), and 17
and 24 lesions with any uncovered struts (difference 211.1%,
95% CI 244.8 to 19.7, P ¼ 0.48).
A total of 28 and 86 struts were malapposed in the BES and SES
groups, respectively (difference 20.2%, 95% CI 20.8 to 0.2, P ¼
0.19). Results were similar in adjusted analyses (difference 20.3%,
95% CI 20.6 to 0.0, P ¼ 0.08, Table 6). A total of 0 and 1 lesions
had10%malapposed struts in the BES and SES groups, respectively
(difference 20.4%, 95% CI 27.6 to 0.0, P ¼ 0.05), one and six
lesions had 5% malapposed struts (difference 28.4%, 95% CI
225.5 to20.1, P ¼ 0.05), and 11 and 17 lesions had anymalapposed
struts (difference 213.7%, 95% CI 247.8 to 20.9, P ¼ 0.42).
A total of 11 and 41 struts were both malapposed and uncov-
ered in the BES and SES groups, respectively (difference 20.1%,
95% CI 20.4 to 0.0, P ¼ 0.13). Results were similar in adjusted
analyses (difference 20.2%, 95% CI 20.6 to 0.0, P ¼ 0.08,
Table 6). None of the lesions had 10% struts, which were both
malapposed and uncovered, zero and two lesions had 5% (differ-
ence 25.1%, 95% CI 220.1 to 1.5, P ¼ 0.12), and 6 and 14 lesions
had any malapposed and uncovered struts (difference 221.0%,
95% CI 248.7 to 5.9, P ¼ 0.12).
Figure 4 presents the distribution of neointimal thickness across
all struts. In 67% of all struts, tissue thickness was below 100 mm,
the resolution of IVUS. The average tissue thickness was 67.6 mm
(95% CI 56.0–81.7 mm) in the BES and 57.1 mm (95% CI 48.4–
67.6 mm) in the SES group (P ¼ 0.19).
Safety of optical coherence tomography
Mean contrast volume used for coronary flushing was 37.4 mL (SD
12.3). There were no cases of contrast-induced nephropathy. In
one patient, contrast flushing during OCT imaging induced ventri-
cular fibrillation. Sinus rhythm was promptly restored following
external cardioversion. Deep guide catheter intubation during con-
trast injection was thought to have caused the arrhythmia. The
patient made an uneventful recovery and was discharged as
planned the following day.
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Table 2 Baseline characteristics of lesions
Biolimus-eluting stent Sirolimus-eluting stent P-value
Target lesion coronary artery 0.18
Left main 0/29 (0.0%) 0/35 (0.0%)
Left anterior descending 15/29 (51.7%) 12/35 (34.3%)
Left circumflex 3/29 (10.3%) 10/35 (28.6%)
Right 11/29 (37.9%) 13/35 (37.1%)
Bypass graft 0/29 (0.0%) 0/35 (0.0%)
De novo lesions 27/29 (93.1%) 34/35 (97.1%) 0.45
Lesion length (mm)
Assesseda 14.3 (14.5) 13.3 (9.1) 0.80
Assessed or estimatedb 17.3 (14.7) 20.9 (19.0) 0.41
Reference vessel diameter (mm)b 2.7 (0.6) 2.4 (0.5) 0.02
Minimal lumen diameter (mm)c 0.93 (0.60) 0.63 (0.53) 0.04
Stenosis (% lumen diameter)c 66.9 (20.3) 73.4 (21.0) 0.20
Total occlusion 5/28 (17.9%) 9/34 (26.5%) 0.42
Severe calcification 3/29 (10.3%) 3/33 (9.1%) 0.87
Pre-procedure TIMI flow 0.35
Grade 1 5/28 (17.9%) 9/34 (26.5%)
Grade 2 1/28 (3.6%) 3/34 (8.8%)
Grade 3 1/28 (3.6%) 4/34 (11.8%)
Grade 4 21/28 (75.0%) 18/34 (52.9%)
Data are mean (SD) or number of lesions/number assessed (%). Assessments were not possible in all 64 lesions with angiographic assessments and therefore the number of lesions
differs according to outcome. P-values are frommixed maximum-likelihood models, which allowed for the correlation of more than one lesion within patients, except for P-values
referring to target lesion coronary artery and pre-procedure TIMI flow, which are from Fisher’s exact test. TIMI, thrombolysis in myocardial infarction.
aTwenty-one lesions assessed in the biolimus-eluting stent group and 22 in the sirolimus-eluting stent group.
bTwenty-nine lesions assessed in the biolimus-eluting stent group and 35 in the sirolimus-eluting stent group.
cTwenty-seven lesions assessed in the biolimus-eluting stent group and 34 in the sirolimus-eluting stent group.
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Discussion
The LEADERS trial is the first, large, multi-centre randomized
study to incorporate an OCT sub-study to help address the
issue of tissue coverage following DES implantation. Quantitative
coronary angiography and IVUS lack the spatial resolution to accu-
rately quantify tissue coverage. Hence, OCT, with a resolution of
approximately 15 mm, is ideal for the purpose of comparing the
presence and extent of tissue coverage in the two stents studied.
The SES was the first DES to be introduced and is covered by two
layers of durable polymer with a top coating for slow drug release.
The availability of up to 8 years clinical follow-up after SES implan-
tation and evidence of greater efficacy in reducing restenosis and
late lumen loss in direct or indirect comparison with other
DESs9,18–20 have made SESs the current gold standard of treatment.
Pathological follow-up examinations at autopsy following implan-
tation of an SES have shown that neointimal healing is still incomplete
after 16months,21 a specific problem that may prolong the period of
thrombotic risk. Struts directly exposed to the blood flow may be
surrogates for thrombotic risk given that pathological studies have
identified a lack of tissue healing in cases of stent thrombosis.6,22 Fur-
thermore, exposed struts, particularly if malapposed, are also likely
to result in flow disturbance that can be pro-thrombotic.23,24
The polymer coating as a system for drug delivery has been impli-
cated as being pro-inflammatory and retard healing and coverage.22 A
number of OCT results after implantation of DESs have been
reported13,14,25–27 Takano et al.7,14 undertook OCT examination at
3 months and 2 years following SES implantation in 21 patients. The
thickness of tissue at 2 years was greater than that at 3 months
(71+93 vs. 29+41 mm, respectively; P, 0.001). Frequency of
struts with no visible coverage was lower in the 2-year group com-
pared to the 3-month group (5 vs. 15%, respectively; P, 0.001),
with a prevalence of patients with uncovered struts between 3
months and 2 years falling from 95 to 81%, respectively. Matsumoto
et al.13 examined 57 SESs in 34 patients at 6 months after implantation
and found the median tissue thickness to be 52.5 mm with 89% of
struts covered and 11% exposed. These studies are limited by the
small sample size and by the fact the population consisted almost
exclusively of single short SES because of the limitations of the
balloon occlusive technique used for OCT image acquisition.
Recently, results from a randomized trial of OCT in long lesions
requiring overlap stenting were presented.26 In 22 patients receiv-
ing SESs, 6% of all struts had no visible coverage at 6-month
follow-up. In our study, 407 out of 6476 struts were uncovered
among patients allocated to SESs, which corresponds to approxi-
mately 6% in a naive analysis ignoring the clustered nature of the
data. Accounting for the nature of the data in a Bayesian hierarch-
ical random-effects model yields a lower estimate of 2.1% in this
study, which suggests that the type of analysis has dramatic
effects not only on the precision of estimates, but also on their
estimated magnitude.
We exclusively used a non-occlusive method to acquire OCT
images performed during contrast flush via the guiding catheter
with no requirement for the cumbersome occlusion balloon
method used in all the other published studies. This ensured that
the broad ‘all-comer’ inclusion criteria for the LEADERS trial
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Table 3 Procedural results
Biolimus-eluting stent Sirolimus-eluting stent Difference
Estimate (95% CI) P-value
No. of study stents per lesiona 1.4 (0.7) 1.7 (0.9) 20.3 (20.7 to 0.1) 0.18
Maximal stent diameter per lesion (mm)a 3.1 (0.4) 2.9 (0.5) 0.2 (20.1 to 0.4) 0.17
Total stent length per lesion (mm)a 26.7 (18.6) 33.5 (24.3) 25.7 (219.4 to 7.0) 0.38
Direct stenting 15/29 (51.7%) 14/35 (40.0%) 11.7 (210.9 to 34.4) 0.31
Implantation of study stent 29/29 (100.0%) 35/35 (100.0%) 0 (n/e) 1.00
Device success 29/29 (100.0%) 35/35 (100.0%) 0 (n/e) 1.00
Lesion success 29/29 (100.0%) 35/35 (100.0%) 0 (n/e) 1.00
Minimal lumen diameter (mm)a
In-stent 2.40 (0.47) 2.22 (0.43) 0.18 (20.05 to 0.40) 0.13
In-segment 2.06 (0.55) 1.95 (0.45) 0.09 (20.17 to 0.35) 0.49
Diameter stenosis (%)a
In-stent 13.13 (6.37) 15.18 (6.97) 22.12 (25.74 to 1.50) 0.25
In-segment 23.24 (8.27) 22.90 (7.70) 0.64 (23.54 to 4.83) 0.76
Acute gain (mm)b
In-stent 1.50 (0.57) 1.58 (0.45) 20.05 (20.36 to 0.25) 0.73
In-segment 1.15 (0.63 1.31 (0.44) 20.17 (20.50 to 0.15) 0.30
Data are mean (SD) or number of lesions/number assessed (%), unless otherwise stated. Mixed maximum-likelihood models were used for comparisons between groups to
account for the correlation of multiple lesions within patients. n/e, CI for difference in percentages could not be estimated.
aTwenty-nine lesions assessed in the biolimus-eluting stent group and 35 in the sirolimus-eluting stent group.
bTwenty-seven lesions assessed in the biolimus-eluting stent group and 34 in the sirolimus-eluting stent group.
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were reproduced in the OCT sub-study in which ostial, proximal,
and multi-vessel stenting were all imaged by OCT.
The OCT results of our study in all comers with great lesion
complexity confirms previous studies by showing that only a
small percentage of SES struts are not covered with tissue 9
months after SES implantation. Still, only a minority of lesions
after SES implantation had full lesion coverage at 9 months and
half the lesions treated had less than 95% tissue coverage. The
absence of longitudinal studies correlating intimal coverage of
DESs and late stent thrombosis is the main limitation of this and
other OCT studies at this stage. Although OCT has a high resol-
ution permitting clear visualization of the tissue surrounding
stent struts, we can only hypothesize as to its exact composition,
particularly around unapposed struts. With its homogenous, highly
reflective appearance, it is likely in keeping with neointimal prolifer-
ation (especially at 9-month follow-up) rather than fibrin or unen-
dothelialized tissue that typically has a heterogeneous appearance.
Contemporary DES technologies are now geared towards elim-
inating the potential causes of poor tissue coverage and hence, to
develop a stent that has similar anti-proliferative properties to the
first-generation SES but with the added advantage of no or a lower
risk of late stent thrombosis. The low incidence of stent thrombo-
sis with first-generation DESs also means that comparison studies
need thousands of patients and several years of follow-up to show
differences in clinical outcome and this makes any surrogate end-
point valuable.
The BES did not differ from the SES in the quantity of tissue over-
lying the stent struts (67.6 mm compared with 57.1 mm for the SES,
P ¼ 0.19), suggesting similar efficacy in preventing restenosis to
SESs, as confirmed by the results of the main study.8 The BES con-
tained fewer exposed stent struts, which translated into more than
95% of the stents showing near-complete coverage vs. less than
two-thirds in the SES group. These results suggest that better tissue
coverage may be achieved with the BES compared with the SES.
The presence of abluminal coating and the biodegradable
polymer is not the only reason that possibly explained this differ-
ence. The better apposition observed at 9-month follow-up can be
explained by fewer instances of late acquired malapposition due to
the absence of hypersensitivity reaction against the biodegradable
polymer. It may also reflect a better initial apposition immediately
after stent implantation, allowed by the thinner more pliable struts
and different stent design. A previous study using OCT immedi-
ately following SESs or paclitaxel-eluting stents (PESs; Taxus,
Boston Scientific, Natick, USA) implantation found a significantly
higher proportion of SES struts to be malapposed compared
with the PES.28 This is likely, in part, to be due to the closed cell
design and the thicker strut profile of the SES.28
Study limitations
The presence or absence of neointimal coverage is limited by the
resolution of OCT and struts reported as bare could have a very
thin covering of tissue (,10 mm), although the biological protec-
tion offered by such a thin coverage is debatable.29 Furthermore,
the number of patients included was small, enrolled only in two
centres, and differences in patient and lesion characteristics may
have clouded our conclusions despite the randomized nature of
the trial and the robustness of results to adjusting for lesion
characteristics.
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Table 4 Angiographic follow-up results
Biolimus-eluting stent Sirolimus-eluting stent Difference
Estimate (95% CI) P-value
Reference vessel diameter (mm)a 2.84 (0.44) 2.60 (0.57) 0.23 (20.05 to 0.52) 0.11
Minimal lumen diameter (mm)
In-stent 2.24 (0.69) 2.03 (0.57) 0.19 (20.15 to 0.53) 0.27
In-segment 2.01 (0.63) 1.83 (0.54) 0.15 (20.17 to 0.47) 0.37
Diameter stenosis (%)b
In-stent 21.54 (19.51) 21.89 (13.56) 20.10 (29.21 to 9.01) 0.98
In-segment 27.85 (17.87) 27.55 (12.33) 0.69 (27.61 to 8.99) 0.87
Late loss (mm)b
In-stent 0.16 (0.41) 0.18 (0.39) 0.00 (20.22 to 0.22) 0.99
In-segment 0.06 (0.35) 0.09 (0.36) 20.03 (20.22 to 0.16) 0.77
Binary restenosisb
In-stent 2/29 (6.9%) 1/33 (3.0%) 3.9 (27.1 to 14.9) 0.49
In-segment 2/29 (6.9%) 2/33 (6.1%) 0.8 (211.4 to 13.1) 0.89
Data are mean (SD) or number of lesions/number assessed (%). Angiographic assessments were not possible in all lesions, therefore the number of lesions differs according to
outcome. Mixed maximum-likelihood models were used for comparisons between groups to account for the correlation of multiple lesions within patients. 95% CI and P-values
are two-sided, from superiority testing. Twenty-nine lesions were assessed in the biolimus-eluting stent group and 35 in the sirolimus-eluting stent group unless indicated
otherwise.
aTwenty-eight lesions assessed in the biolimus-eluting stent group and 33 in the sirolimus-eluting stent group.
bTwenty-nine lesions assessed in the biolimus-eluting stent group and 33 in the sirolimus-eluting stent group.
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The choice of a 9-month OCT examination was empiric and in
line with the follow-up arm of the main LEADERS trial. An earlier
OCT assessment may have helped to assess the rapidity of tissue
coverage, while a later examination may have offered more rel-
evant information for the process of very late (.1 year) stent
thrombosis. A recent OCT follow-up study with SESs confirmed
the presence of ongoing uncovered stent struts even at 2 years
follow-up, indicating that failure of early tissue coverage might
become a permanent observation.7 OCT was not carried out
immediately following stent implantation so that the mechanism
of malapposition of struts cannot be accurately determined so
that we are unable to distinguish persisting or late acquired
malapposition.
Only one autopsy study convincingly linked stent coverage and
thrombosis.6 This study did not offer a cut-off percentage of
uncovered stents associated with stent thrombosis and focused
on the prevalence of uncovered struts in individual cross-sections
(information we also convey in Figure 3). The division into three
classes with complete (100%) and 95 and 90% coverage is arbitrary
but corresponds to pre-specified definitions of secondary
Figure 3 Graphical representation of stent coverage in lesions. Grey horizontal bars represent lesions. Uncovered struts are represented by
red lines. *Lesions located in small vessels.
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endpoints. Only prolonged follow-up and larger studies will answer
the question of the appropriate cut-off to be used to identify
patients at clinically relevant increased risk of stent thrombosis.
Multilevel analysis was used in this study as standard statistical
approaches are inappropriate in data with significant clustering. In
fact, even though more than 10 000 strut-related data points
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Table 5 Results of principal analyses
Percentage (95% CI) Difference in percentage
Biolimus-eluting stent Sirolimus-eluting stent Estimate (95% CI) P-value
Uncovered struts 0.6 (0.2–1.6) 2.1 (0.9–4.4) 21.4 (23.7 to 0.0) 0.04
Lesions with
At least 10% uncovered struts 2.2 (0.2–12.1) 13.3 (3.4–33.5) 210.2 (230.9 to 1.3) 0.08
At least 5% uncovered struts 3.8 (0.4–16.9) 38.3 (16.4–65.5) 233.1 (261.7 to 210.3) ,0.01
Any uncovered struts 63.3 (35.2–86.4) 74.9 (51.7–91.8) 211.1 (244.8 to 19.7) 0.48
Malapposed struts 0.2 (0.1–0.5) 0.4 (0.2–1.0) 20.2 (20.8 to 0.2) 0.19
Lesions with
At least 10% malapposed struts 0.0 (0.0–0.3) 0.5 (0.0–7.6) 20.4 (27.6 to 0.0) 0.05
At least 5% malapposed struts 0.9 (0.0–8.2) 10.0 (2.2–27.2) 28.4 (225.5 to 20.1) 0.05
Any malapposed struts 33.5 (12.3–60.1) 47.8 (24.0–72.4) 213.7 (247.8 to 20.9) 0.42
Malapposed and uncovered struts 0.1 (0.0–0.2) 0.2 (0.1–0.5) 20.1 (20.4 to 0.0) 0.13
Lesions with
At least 10% malapposed and uncovered struts 0.0 (0.0–0.1) 0.0 (0.0–0.1) 0.0 (0.0 to 0.1) 0.70
At least 5% malapposed and uncovered struts 0.8 (0.0–7.4) 6.5 (1.2–21.8) 25.1 (220.1 to 1.5) 0.12
Any malapposed and uncovered struts 12.9 (2.8–34.0) 35.5 (14.4–59.6) 221.0 (248.7 to 5.9) 0.12
Four thousand five hundred and eight struts in 29 lesions assessed in the biolimus-eluting stent group and 6083 struts in 35 lesions in the sirolimus-eluting stent group. 95% CI and
P-values derived from Bayesian hierarchical models are two-sided, from superiority testing.
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Table 6 Sensitivity analyses
Percentage (95% CI) Difference in percentage
Biolimus-eluting stent Sirolimus-eluting stent Estimate (95% CI) P-value
Uncovered struts 0.7 (0.3 to 1.8) 2.7 (1.1 to 6.4) 22.0 (25.7 to 20.1) 0.04
Lesions with
At least 10% uncovered struts 1.4 (0.1 to 10.6) 17.1 (3.4 to 45.1) 214.7 (243.3 to 0.0) 0.05
At least 5% uncovered struts 3.5 (0.3 to 18.1) 50.5 (20.1 to 80.2) 245.5 (276.9 to -14.3) ,0.01
Any uncovered struts 70.0 (37.8 to 91.2) 80.5 (53.3 to 94.8) 29.5 (244.9 to 22.8) 0.54
Malapposed struts 0.2 (0.1 to 0.5) 0.5 (0.2 to 1.3) 20.3 (20.6 to 0.0) 0.08
Lesions with
At least 10% malapposed struts n/e n/e n/e n/e
At least 5% malapposed struts 0.3 (0.0 to 4.2) 6.7 (0.8 to 26.3) 25.9 (225.5 to 20.2) 0.04
Any malapposed struts 31.4 (9.2 to 64.2) 49.8 (20.1 to 78.7) 216.9 (256.5 to 24.6) 0.42
Malapposed and uncovered struts 0.1 (0.0 to 0.2) 0.3 (0.1 to 0.7) 20.2 (20.6 to 0.0) 0.08
Lesions with
At least 10% malapposed and uncovered struts n/e n/e n/e n/e
At least 5% malapposed and uncovered struts 0.2 (0.0 to 3.7) 4.3 (0.6 to 22.5) 23.8 (221.9 to 0.2) 0.06
Any malapposed and uncovered struts 12.3 (2.3 to 38.5) 37.8 (13.9 to 69.5) 224.0 (259.8 to 8.8) 0.14
Four thousand five hundred and eight struts in 29 lesions assessed in the biolimus-eluting stent group and 6083 struts in 35 lesions in the sirolimus-eluting stent group. 95% CI and
P-values derived from Bayesian hierarchical model are two-sided, from superiority testing. All analyses are adjusted for pre-procedure lesion length, reference vessel diameter,
number of implanted study stents, and presence of stent overlap. n/e, could not be estimated.
P. Barlis et al.174
were available, these were not independent observations: struts
within the same lesion and lesions within the same patient are
likely to be similar and a fundamental assumption of classic statisti-
cal tests would be violated if these tests were used to analyse
strut-related data points. A large proportion of lesions in both
groups had no or very few uncovered struts at all, and the Bayesian
model allowed appropriate weighting of these lesions. Estimates
will therefore be more conservative than estimates from naı¨ve ana-
lyses comparing the proportion of uncovered struts between
groups. Formal sample size calculations are difficult in this situation
and no power calculation algorithm exists, which is based on gen-
erally accepted assumptions regarding intra-cluster correlation or
design factors.
Conclusions
Strut coverage appears to be more complete in patients allocated
to BESs as compared with SESs. The impact of this difference on
clinical outcome and, in particular, on the risk of late stent throm-
bosis is yet to be determined.
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